Tipepidine as adjuvant therapt in major depression

Tipepidine as adjuvant therapt in major depression: a randomised controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N122

Enrollment

Registered

2019-10-19

Start date

2019-10-31

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder. Major depressive disorder, single episode, moderate

Interventions

Intervention 1: Intervention group: tablet citalopram 40 mg/day plus Capsule tipipedine 30 mg BID as intervention group for 6 weeks. Intervention 2: Intervention group: tablet citalopram 40 mg/day plu

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Presence of Major Depressive Disorder based on DSM-5 criteria Baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 19

Exclusion criteria

Exclusion criteria: Presence of psychosis Any other mental disorder Hypothyroidism Cardiovascular disease Pregnancy or nursing women receiving ECT during last two months substance use receiving any other psychotropic medications

Design outcomes

Primary

Measure	Time frame
Severity of depression. Timepoint: Baseline and weeks 2,4 and 6. Method of measurement: by Hamiltion Depression Rating Scale 17-Item.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026